

Carl A Olsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11699788/publications.pdf>

Version: 2024-02-01

148
papers

7,846
citations

50276

46
h-index

53230

85
g-index

161
all docs

161
docs citations

161
times ranked

3545
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. <i>Journal of Urology</i> , 1992, 147, 815-816.	0.4	669
2	The Use of Prostate Specific Antigen Density to Enhance the Predictive Value of Intermediate Levels of Serum Prostate Specific Antigen. <i>Journal of Urology</i> , 1992, 147, 817-821.	0.4	573
3	Stress Incontinence: Classification and Surgical Approach. <i>Journal of Urology</i> , 1988, 139, 727-731.	0.4	375
4	Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 958-958.	1.6	308
5	Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. <i>Urology</i> , 1994, 43, 765-775.	1.0	287
6	The Flow Rate Nomogram: I. Development. <i>Journal of Urology</i> , 1979, 122, 665-668.	0.4	283
7	Case 13-1976. <i>New England Journal of Medicine</i> , 1976, 294, 712-720.	27.0	212
8	Enhanced expression of thec-myc protooncogene in high-grade human prostate cancers. <i>Prostate</i> , 1987, 11, 327-337.	2.3	180
9	The Flow Rate Nomogram: II. Clinical Correlation. <i>Journal of Urology</i> , 1980, 123, 208-210.	0.4	177
10	Transition Zone Index as a Method of Assessing Benign Prostatic Hyperplasia: Correlation with Symptoms, Urine Flow and Detrusor Pressure. <i>Journal of Urology</i> , 1995, 154, 1764-1769.	0.4	170
11	Rapid reduction in blood flow to the rat ventral prostate gland after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. , 1998, 36, 201-206.		154
12	Phenoxybenzamine in Neurogenic Bladder Dysfunction. II. Clinical Considerations. <i>Journal of Urology</i> , 1973, 110, 653-656.	0.4	139
13	Phenoxybenzamine in Neurogenic Bladder Dysfunction. I. A Theory of Micturition. <i>Journal of Urology</i> , 1973, 110, 650-652.	0.4	135
14	Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. <i>Prostate</i> , 1988, 13, 119-130.	2.3	117
15	Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. <i>Urology</i> , 1999, 53, 440-445.	1.0	116
16	Ureteral Reconstruction and Bypass: Experience with Ileal Interposition, The Boari Flap-Psoas Hitch and Renal Autotransplantation. <i>Journal of Urology</i> , 1990, 143, 20-23.	0.4	112
17	Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. <i>Urology</i> , 2006, 67, 260-264.	1.0	107
18	Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. <i>Cancer</i> , 1995, 75, 1642-1648.	4.1	105

#	ARTICLE	IF	CITATIONS
19	PSA DENSITY (PSAD). Urologic Clinics of North America, 1993, 20, 653-663.	1.8	103
20	The Incidence of Multifocal Renal Cell Carcinoma in Patients Who are Candidates for Partial Nephrectomy. Journal of Urology, 1995, 154, 968-971.	0.4	98
21	Microvessel Density as a Predictor of PSA Recurrence After Radical Prostatectomy. American Journal of Clinical Pathology, 2000, 113, 555-562.	0.7	94
22	Preoperative Reverse Transcriptase Polymerase Chain Reaction for Prostate Specific Antigen Predicts Treatment Failure Following Radical Prostatectomy. Journal of Urology, 1996, 155, 1557-1562.	0.4	92
23	Immunologic Reduction of Bladder Cancer Recurrence Rate. Journal of Urology, 1974, 111, 173-176.	0.4	88
24	Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology, 1999, 54, 1039-1043.	1.0	86
25	Gene expression in response to acute unilateral ureteral obstruction. Kidney International, 1989, 35, 1315-1319.	5.2	81
26	Characterization of the Products of a Gene Expressed During Androgen-Programmed Cell Death and their Potential use as a Marker of Urogenital Injury. Journal of Urology, 1990, 143, 407-413.	0.4	79
27	URINARY CONTINENCE AFTER RADICAL PROSTATECTOMY: THE COLUMBIA EXPERIENCE. Journal of Urology, 1998, 159, 1276-1280.	0.4	79
28	Laser tissue soldering in urinary tract reconstruction: First human experience. Urology, 1995, 46, 261-266.	1.0	78
29	SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2001, 166, 882-886.	0.4	78
30	Conservative Management of Renal Artery Embolus. Journal of Urology, 1973, 109, 138-143.	0.4	73
31	Molecular Staging of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen. Journal of Urology, 1995, 153, 1373-1378.	0.4	73
32	Urological Neurology and Urodynamics: Urodynamics and the Etiology of Post-Prostatectomy Urinary Incontinence: The Initial Columbia Experience. Journal of Urology, 1995, 153, 1034-1037.	0.4	72
33	Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. , 1997, 32, 246-258.		69
34	CAN PERINEURAL INVASION ON PROSTATE NEEDLE BIOPSY PREDICT PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY?. Journal of Urology, 1999, 162, 103-106.	0.4	68
35	Outcomes of Distal Ureteral Reconstruction Through Reimplantation With Psoas Hitch, Boari Flap, or Ureteroneocystostomy for Benign or Malignant Ureteral Obstruction or Injury. Urology, 2013, 82, 231-236.	1.0	68
36	Prognostic Variables in Patients with Transitional Cell Carcinoma of the Renal Pelvis and Proximal Ureter. Journal of Urology, 1987, 138, 1144-1145.	0.4	67

#	ARTICLE	IF	CITATIONS
37	Renal Growth Factor Expression during the Early Phase of Experimental Hydronephrosis. Journal of Urology, 1992, 148, 510-514.	0.4	66
38	The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. , 1999, 86, 492-497.		64
39	Urologists On a Tightrope: Coping with a Changing Economy. Journal of Urology, 1994, 151, 1-4.	0.4	62
40	DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER. Journal of Urology, 2000, 163, 834-837.	0.4	62
41	SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney International, 1991, 39, 1098-1103.	5.2	58
42	Epidermal growth factor suppresses renal tubular apoptosis following ureteral obstruction. Urology, 1997, 49, 973-980.	1.0	58
43	Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a). BJU International, 2005, 95, 27-30.	2.5	54
44	Metastatic infection secondary to genitourinary tract sepsis. American Journal of Medicine, 1976, 61, 351-360.	1.5	50
45	Multiple primary neoplasms in association with prostate cancer in black and white patients. Cancer, 1987, 59, 380-384.	4.1	50
46	PRETREATMENT PROSTATE SPECIFIC ANTIGEN DOUBLING TIMES: USE IN PATIENTS BEFORE RADICAL PROSTATECTOMY. Journal of Urology, 1997, 158, 1876-1879.	0.4	49
47	Differential Diagnosis of Prostatism: a 12-year Retrospective Analysis of Symptoms, Urodynamics and Satisfaction with Therapy. Journal of Urology, 1996, 155, 1305-1308.	0.4	48
48	The Ileal Ureter Neobladder is Associated with a High Success and a Low Complication Rate. Journal of Urology, 1996, 155, 1585-1588.	0.4	48
49	CASTRATION INDUCES ACUTE VASOCONSTRICTION OF BLOOD VESSELS IN THE RAT PROSTATE CONCOMITANT WITH A REDUCTION OF PROSTATIC NITRIC OXIDE SYNTHASE ACTIVITY. Journal of Urology, 1999, 162, 1527-1531.	0.4	47
50	Pulmonary Cancer Metastatic to the Kidneyâ€”a Common Renal Neoplasm. Journal of Urology, 1971, 105, 492-496.	0.4	46
51	Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy. , 1999, 84, 360-364.		46
52	Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management. Cancer, 1994, 74, 1667-1673.	4.1	44
53	The Predictive Value of Flow Cytometry and Urinary Cytology in the Followup of Patients with Transitional Cell Carcinoma of the Bladder. Journal of Urology, 1992, 148, 293-296.	0.4	43
54	Flow cytometry: Role in monitoring transitional cell carcinoma of bladder. Urology, 1986, 28, 15-20.	1.0	41

#	ARTICLE	IF	CITATIONS
55	A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. , 1999, 82, 846-852.		41
56	Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies. PLoS ONE, 2015, 10, e0143404.	2.5	41
57	Continent urinary diversion. Urologic Clinics of North America, 1999, 26, 125-147.	1.8	40
58	Effect of demographic factors, urinary peak flow rates, and Boyarsky Symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology, 1995, 45, 398-405.	1.0	39
59	Combined Boari Bladder Flap-Psoas Bladder Hitch Procedure in Ureteral Replacement. Scandinavian Journal of Urology and Nephrology, 1986, 20, 279-284.	1.4	38
60	The Phentolamine Test in Neurogenic Bladder Dysfunction. Journal of Urology, 1977, 117, 481-485.	0.4	37
61	REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION ASSAYS FOR PROSTATE CANCER. Urologic Clinics of North America, 1997, 24, 367-378.	1.8	36
62	Acid phosphatase localization in prostatic carcinoma. A comparison of monoclonal antibody to heteroantisera. Cancer, 1983, 52, 1642-1646.	4.1	35
63	Abnormal prostate development in C3(1)-bcl-2 transgenic mice. , 1997, 32, 16-26.		35
64	Clinical Use of Rabbit Antihuman Lymphocyte Globulin in Cadaver-Kidney Transplantation. New England Journal of Medicine, 1971, 284, 1109-1115.	27.0	34
65	Renal Autotransplantation for Recurrent Renal Colic. Journal of Urology, 1980, 123, 467-473.	0.4	33
66	Neurotrophic Factors in the Rat Penis. Journal of Urology, 1994, 152, 2167-2172.	0.4	33
67	Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology, 2006, 67, 942-945.	1.0	33
68	Reevaluation of TNM staging of renal cortical tumors: Recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology, 2006, 68, 287-291.	1.0	31
69	Effects of Levodopa on the Bladder Outlet. Journal of Urology, 1975, 113, 803-805.	0.4	28
70	Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology, 1994, 43, 645-648.	1.0	28
71	Detection and Treatment of Prostate Cancer: Perspective of the Urologist. Journal of Urology, 1994, 152, 1695-1699.	0.4	28
72	The American Urological Association Symptom Score in the Evaluation of Men With Lower Urinary Tract Symptoms: at 2 years of followup, does it work?. Journal of Urology, 1996, 155, 1971-1974.	0.4	28

#	ARTICLE	IF	CITATIONS
73	Hypospadias repair by laser tissue soldering: Intraoperative results and follow-up in 30 children. <i>Urology</i> , 1996, 48, 616-623.	1.0	28
74	THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2000, 163, 1413-1418.	0.4	28
75	Flow cytometric analysis of localized adenocarcinoma of the prostate: The use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy. <i>Prostate</i> , 1990, 17, 155-164.	2.3	27
76	The evolving role of partial nephrectomy in the management of renal cell carcinoma. <i>Current Oncology Reports</i> , 2003, 5, 239-244.	4.0	27
77	Chromosomal assignment of the human homologue encoding SGP-2. <i>Biochemical and Biophysical Research Communications</i> , 1990, 172, 160-164.	2.1	25
78	Racial or Ethnic and Socioeconomic Disparities in Prostate Cancer Survivors' Prostate-specific Quality of Life. <i>Urology</i> , 2018, 112, 132-137.	1.0	24
79	Urethrocavernous Fistula: Complication of Cavernospongiosal Shunt. <i>Journal of Urology</i> , 1972, 108, 750-751.	0.4	23
80	Complications of Artificial Urinary Sphincter Around Intestinal Segments in Reconstructed Exstrophy Patients. <i>Journal of Urology</i> , 1987, 138, 1123-1125.	0.4	23
81	Molecular staging of genitourinary malignancies. <i>Urology</i> , 1996, 47, 948-958.	1.0	23
82	Prostatic and Periprostatic Interstitial Temperature Measurements in Patients Treated with Transrectal Thermal Therapy (Local Intracavitary Microwave Hyperthermia). <i>Journal of Urology</i> , 1992, 147, 1562-1565.	0.4	22
83	RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. <i>Urology</i> , 2003, 61, 967-971.	1.0	20
84	THE ROLE OF THE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION ASSAY FOR PROSTATE-SPECIFIC ANTIGEN IN THE SELECTION OF PATIENTS FOR RADICAL PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 1996, 23, 541-549.	1.8	19
85	Galactosyl receptor, a cell surface C-type lectin of normal and tumoral prostate epithelial cells with binding affinity to endothelial cells. <i>Prostate</i> , 2000, 43, 175-183.	2.3	19
86	Blood-based RT-PCR assays of MN/CA9 or PSMA: clinical application in renal cancer patients. <i>Urology</i> , 2000, 56, 393-398.	1.0	19
87	Changes in Prognostic Significance and Predictive Accuracy of Gleason Grading System Throughout PSA Era: Impact of Grade Migration in Prostate Cancer. <i>Urology</i> , 2007, 70, 706-710.	1.0	17
88	Adjuvant chemotherapy for stage D1 adenocarcinoma of prostate. <i>Urology</i> , 1983, 21, 270-272.	1.0	16
89	Effect of Rabbit ALG on Cadaver Kidney Transplant Survival. <i>Annals of Surgery</i> , 1972, 176, 521-528.	4.2	15
90	The Relationship of Sperm Counts to Birth Rates: A Population Based Study. <i>Journal of Urology</i> , 1997, 157, 840-843.	0.4	15

#	ARTICLE	IF	CITATIONS
91	Gene Expression in Renal Growth and Regrowth. Journal of Urology, 1988, 140, 1145-1148.	0.4	14
92	The relationship of long term global temperature change and human fertility. Medical Hypotheses, 2003, 61, 21-28.	1.5	14
93	Rapid construction of right colon pouch: Initial clinical experience. Urology, 1994, 43, 228-231.	1.0	13
94	Molecular Staging of Prostate Cancer. III. Effects of Cystoscopy and Needle Biopsy on the Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay. Journal of Urology, 1997, 157, 1748-1751.	0.4	13
95	The Controversy of Single Versus Multistaged Urethroplasty. Journal of Urology, 1978, 120, 414-417.	0.4	12
96	Preoperative Serum Prostate Specific Antigen Remains a Significant Prognostic Variable in Predicting Biochemical Failure After Radical Prostatectomy. Journal of Urology, 2006, 175, 1663-1667.	0.4	12
97	Reconstruction of urinary and gastrointestinal tracts in total pelvic exenteration: Experience at columbia-presbyterian medical center. Urology, 1994, 44, 666-670.	1.0	11
98	Development of a carbon dioxide laser cystoscope. Lasers in Surgery and Medicine, 1980, 1, 183-190.	2.1	10
99	Continent Urinary Diversion. Journal of Urology, 1984, 132, 1157-1158.	0.4	10
100	New look at pelvic exenteration. Urology, 1976, 7, 355-361.	1.0	9
101	Benefits and complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. Prostate, 1980, 1, 345-349.	2.3	9
102	Pediatric Continent Reservoirs and Colocystoplasty Created with Absorbable Staples. Journal of Urology, 1996, 156, 614-617.	0.4	9
103	The Transverse Upper Abdominal "Chevron" Incision in Urological Surgery. Journal of Urology, 1968, 99, 528-532.	0.4	8
104	Thrombocytopenia with External Genital Gangrene. Journal of Urology, 1974, 112, 208-210.	0.4	8
105	Adjunctive therapy with interstitial irradiation for prostate cancer. Urology, 1982, 19, 395-398.	1.0	8
106	A Surgical Procedure Suggested for Certain Cases of Reduplicated Ureter. Journal of Urology, 1971, 105, 790-793.	0.4	6
107	Contemporary cystectomy versus preoperative radiation plus cystectomy for bladder cancer. Urology, 1988, 32, 485-491.	1.0	6
108	Prostatic expression of hensen, a protein implicated in epithelial terminal differentiation. Prostate, 2001, 49, 9-18.	2.3	6

#	ARTICLE	IF	CITATIONS
109	PEDICLE PATCH URETHROPLASTY FOR CURE OF URETHRAL STRICTURE. <i>Plastic and Reconstructive Surgery</i> , 1973, 51, 1-7.	1.4	5
110	Does size matter? The significance of prostate size on pathologic and functional outcomes in patients undergoing robotic prostatectomy. <i>Arab Journal of Urology Arab Association of Urology</i> , 2011, 9, 159-164.	1.5	5
111	Absorbable Stapling Techniques in Bowel Reservoirs. <i>Atlas of the Urologic Clinics of North America</i> , 1995, 3, 69-80.	0.0	5
112	Urology Peer Review at the National Institutes of Health. <i>Journal of Urology</i> , 1995, 154, 1866-1869.	0.4	4
113	Rapidly Expanding Retroperitoneal Mass. <i>Journal of Urology</i> , 1980, 123, 556-561.	0.4	3
114	Urinary Diversion. <i>Journal of Urology</i> , 1989, 142, 1301-1301.	0.4	3
115	Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 78.e15-78.e21.	1.6	3
116	Molecular Stating of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen. <i>Journal of Urology</i> , 1995, , 1373-1378.	0.4	3
117	Oral Diuretics and Renal Painâ€”A Provocative Test. <i>Journal of Urology</i> , 1972, 108, 25-27.	0.4	2
118	Misonidazole as a Chemosensitizer in the Treatment of the Dunning Prostate Cancer Model. <i>Journal of Urology</i> , 1984, 131, 374-377.	0.4	2
119	Safety of urologic surgical intervention in the elderly. <i>Geriatric Nephrology and Urology</i> , 1992, 2, 105-108.	0.3	2
120	CIRCULATING PROSTATE DERIVED CELLS IN PATIENTS WITH PROSTATE ADENOCARCINOMA. <i>Journal of Urology</i> , 2000, 163, 1631-1631.	0.4	2
121	A recombinant defective adenoviral agent expressing antiâ€”bclâ€”2 ribozyme promotes apoptosis of bclâ€”2â€”expressing human prostate cancer cells. <i>International Journal of Cancer</i> , 1999, 82, 846-852.	5.1	2
122	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5051-5051.	1.6	2
123	Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 272-272.	1.6	2
124	988: Re-Evaluation of the TNM Staging of Conventional Renal Cortical Tumors: Outcome of T1N0M0 and T3AN0M0 Renal Cortical Tumors are Equivalent. <i>Journal of Urology</i> , 2005, 173, 267-267.	0.4	1
125	CASTRATION INDUCES ACUTE VASOCONSTRICTION OF BLOOD VESSELS IN THE RAT PROSTATE CONCOMITANT WITH A REDUCTION OF PROSTATIC NITRIC OXIDE SYNTHASE ACTIVITY. <i>Journal of Urology</i> , 1999, , 1527-1531.	0.4	1
126	SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2001, , 882-886.	0.4	1

#	ARTICLE	IF	CITATIONS
127	Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.. Journal of Clinical Oncology, 2015, 33, e16027-e16027.	1.6	1
128	Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.. Journal of Clinical Oncology, 2016, 34, 193-193.	1.6	1
129	Trends in histology of newly diagnosed prostate cancer subsequent to USPSTF PSA screening recommendation.. Journal of Clinical Oncology, 2016, 34, 68-68.	1.6	1
130	Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 177-177.	1.6	1
131	Utilization and cancer detection by U.S. prostate biopsies (2005-2011).. Journal of Clinical Oncology, 2013, 31, e16076-e16076.	1.6	1
132	Pediatric Continent Reservoirs and Colocystoplasty Created with Absorbable Staples. Journal of Urology, 1996, 156, 614-617.	0.4	1
133	Characteristics and anticancer interventions (ACIs) in African American (AA) and Caucasian (CAU) patients (pts) treated with sipuleucel-T (sip-T): Real-world experience from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, 5025-5025.	1.6	1
134	Editorial comment. Arab Journal of Urology Arab Association of Urology, 2013, 11, 360-361.	1.5	0
135	Re: Management of the Urologic Sepsis Syndrome. European Urology, 2018, 73, 977-978.	1.9	0
136	Re: Jacob A. Burns, Adam B. Weiner, William J. Catalone, et al. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol 2019;75:846â€“52. European Urology, 2019, 76, e98.	1.9	0
137	Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.. Journal of Clinical Oncology, 2021, 39, 195-195.	1.6	0
138	Utilization and cancer detection by U.S. prostate biopsies (2005-2011).. Journal of Clinical Oncology, 2013, 31, 107-107.	1.6	0
139	Urinary function after image-guided intensity modulated radiation therapy (IG-IMRT) of localized prostate cancer.. Journal of Clinical Oncology, 2014, 32, 141-141.	1.6	0
140	Health Risk and Management of Localized Prostate Cancer. Cancer Treatment and Research, 1982, , 121-142.	0.5	0
141	Infectious complications after prostate needle biopsy: Predictors of bacteremia and sepsis.. Journal of Clinical Oncology, 2014, 32, e16035-e16035.	1.6	0
142	Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED.. Journal of Clinical Oncology, 2014, 32, 5040-5040.	1.6	0
143	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, e16503-e16503.	1.6	0
144	A new technique of reporting prostate biopsy to predict prostatectomy outcome.. Journal of Clinical Oncology, 2017, 35, e544-e544.	1.6	0

#	ARTICLE	IF	CITATIONS
145	A new prostate cancer biopsy reporting system with prognostic potential.. Journal of Clinical Oncology, 2017, 35, e16572-e16572.	1.6	0
146	Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study.. Journal of Clinical Oncology, 2018, 36, 234-234.	1.6	0
147	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.. Journal of Clinical Oncology, 2018, 36, 5041-5041.	1.6	0
148	Effects of age on outcomes in men receiving treatment for metastatic castration-resistant prostate cancer (mCRPC): Analysis of Medicare fee for service (FFS) claims data.. Journal of Clinical Oncology, 2020, 38, e17590-e17590.	1.6	0